Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306

被引：0

作者：

Raymond, E. ^{[1
]}

Xu, J. ^{[2
]}

Kato, K. ^{[3
]}

Hubner, R. ^{[4
]}

Shu, Y. ^{[5
]}

Park, S. R. ^{[6
]}

Kojima, T. ^{[7
]}

Wyrwicz, L. S. ^{[8
]}

Tougeron, D. ^{[9
]}

Geboes, K. ^{[10
]}

Van Cutsem, E. ^{[11
,12
]}

Pazo Cid, R. A. ^{[13
]}

Zaanan, A. ^{[14
]}

McLachlan, S-A. ^{[15
]}

Wu, H. ^{[16
]}

Shi, J. ^{[17
]}

Li, L. ^{[18
]}

Yan, S. ^{[19
]}

Yoon, H. ^{[20
]}

机构：

[1] Hop St Louis, AP HP, Clin Dev, Paris, France

[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Gastrointestinal Dept, Beijing 302 Hosp, Beijing, Peoples R China

[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[4] Christie NHS Fdn Trust, Clin Dev, Manchester, Lancs, England

[5] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China

[6] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[9] CHU Poitiers Jean Bernard Hop, Clin Dev, Poitiers, France

[10] UZ Gent Univ Hosp Ghent, Gastroenterol Dept, Ghent, Belgium

[11] Univ Hosp Gasthuisberg, Gastroenterol Digest Oncol, Leuven, Belgium

[12] Univ Leuven KU Leuven, Gastroenterol Digest Oncol, Leuven, Belgium

[13] Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain

[14] Hop Europeen Georges Pompidou, AP HP, Hepatogastroenterol & Digest Oncol, Paris, France

[15] GenesisCare St Vincents Hosp, Clin Dev, Melbourne, Vic, Australia

[16] BeiGene USA Inc, Stat & Data Sci, Ridgefield, NJ USA

[17] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Biomarker, Beijing, Peoples R China

[18] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Dev, Beijing, Peoples R China

[19] BeiGene Beijing Co Ltd, Clin Dev, Beijing, Peoples R China

[20] Mayo Clin, Dept Oncol, Rochester, MN USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.310

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

395MO

引用

页码：S159 / S159

页数：1

共 50 条

[31] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).
Xu, Rui-Hua
Kim, Sung-Bae
Tougeron, David
Zuo, Yunxia
Yang, Haiyuan
Zhang, Juan
Shi, Jingwen
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Cruz-Correa, M.
Oh, D-Y.
Kato, K.
Tabernero, J.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Spigel, D. R.
Wyrwicz, L. S.
Pazo Cid, R. A.
Cubillo Gracian, A.
Li, L.
Xu, Y.
Sheng, T.
Yang, S.
Xu, R-H.
Moehler, M.
ANNALS OF ONCOLOGY, 2024, 35 : S893 - S894
[33] Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
Sun, M.
Spigel, D. R.
Lee, Y-J.
Yoon, H.
Liu, Y.
Ahern, E.
Harris, S.
Lee, G-W.
Yan, D.
Chen, J.
Shiah, H-S.
Deng, T.
Zheng, H.
Tan, W.
Zhou, Z.
Wang, R.
Ba, Y.
ANNALS OF ONCOLOGY, 2023, 34 : S862 - S863
[34] Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).
Shu, Yongqian
Wang, Jufeng
Chen, Zhendong
Kim, Sung-Bae
Lin, Chen-Yuan
Kato, Ken
Van Cutsem, Eric
Du, Wenting
Shi, Jingwen
Xia, Tianyu
Huang, Ruiqi
Li, Qiao
Zhang, Yun
Shen, Zhirong
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 390 - 390
[35] RATIONALE-307: Safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC
Yu, X.
Wang, J.
Hu, Y.
Sun, Y.
Zhao, J.
Yu, Y.
Hu, C.
Yang, K.
Feng, G.
Leaw, S. J.
Yuan, Y.
Lin, X.
Bai, F.
Lu, S.
ANNALS OF ONCOLOGY, 2022, 33 : S37 - S38
[36] Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
Vilbert, Maysa
Priantti, Jonathan N.
Madeira, Thiago
Moraes, Francisco Cezar A.
Tojjari, Alireza
Sahin, Ibrahim Halil
Cavalcante, Ludimila
Saeed, Anwaar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 366 - 366
[37] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
Lei, Ming
Doki, Yuichiro
Kitagawa, Yuko
Kato, Ken
Chau, Ian
Yao, Jin
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Blum Murphy, Mariela A.
Novosiadly, Ruslan
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
[38] Camrelizumab (Camre) plus taxane-based chemotherapy (CT): Clinical outcomes and dynamic monitoring of CEA as a predictive biomarker of response in patients with recurrent or advanced esophageal squamous cell carcinoma (ESCC).
Kong, Cheng
Xu, Jianhua
Jiang, Ming
Zhu, Xiangzhi
Ye, Jinjun
Yu, Shaorong
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39] RATIONALE-302: Tislelizumab vs chemotherapy as secondline treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): Impact on health-related quality of life (HRQoL) in Asian patients
Kim, S-B.
Van Cutsem, E.
Ajani, J. A.
Shen, L.
Barnes, G.
Ding, N.
Tao, A.
Xia, T.
Zhan, L.
Kato, K.
ANNALS OF ONCOLOGY, 2022, 33 : S1464 - S1464
[40] PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
Okadome, Kazuo
Baba, Yoshifumi
Yasuda-Yoshihara, Noriko
Nomoto, Daichi
Yagi, Taisuke
Toihata, Tasuku
Ogawa, Katsuhiro
Sawayama, Hiroshi
Ishimoto, Takatsugu
Iwatsuki, Masaaki
Iwagami, Shiro
Miyamoto, Yuji
Yoshida, Naoya
Watanabe, Masayuki
Komohara, Yoshihiro
Baba, Hideo
CANCER SCIENCE, 2022, 113 (02) : 399 - 410

← 1 2 3 4 5 →